Complex Regional Pain Syndrome (CRPS) was recently designated as a rare disorder by the United States Food & Drug Administration. A disease is considered rare if fewer than 200,000 people in the United States have it. This designation has already generated much greater interest than ever before in CRPS/RSD and is enticing pharmaceutical corporations to consider developing medicines to treat CRPS.
- Clinical trials in CRPS which are recruiting right now
- CRPS Core Clinical Outcome Measures Project: A Delphi study to define internationally agreed core clinical outcome measures for Complex Regional Pain Syndrome clinical research studies (COMPACT‐C)
- Volunteers wanted for studies looking at Complex Regional Pain Syndrome in young people: University of Bath
- exploring how young people with CRPS think about their future – 20-25 minute online survey
- exploring how parents of young people with CRPS think about their child’s future – 20-25 minute online survey
- exploring resilience in parents (couples) of youth with CRPS – Interview
- Read about a multi-national study of patient-defined recovery from RSD: funded by RSDSA
- Final report of RSDSA-funded Genetic study investigating the risk of developing CRPS
- To participate in Investigations of Pathophysiology of Dystonia and Complex Regional Pain Syndrome at the NIH.
- Read about a new Research Study funded by RSDSA
- TARGET Post-Approval Study (TARGET PAS): A Post-Approval Study to Evaluate Targeted SCS Spinal Cord Stimulation (SCS) Dorsal Root Ganglion (DRG) Stimulation for the Management of Moderate to Severe Chronic, Intractable, Pain of the Lower Limbs Due to CRPS Types I and II
- To locate clinical trials in CRPS and RSD, visit clinicaltrials.gov
- RSDSA has ended its 20-year study of the long-term health impact of CRPS on individuals diagnosed with it. We thank everyone who participated. We have begun the analysis of the data and hope to publish the results as soon as possible.